VYXARIQ
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Nov 2024)
What this means for you
This application is over — abandoned 11 Nov 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90430299
- Mark type
- Stylized text
- Filed
- 30 Dec 2020
- Published for opposition
- 10 Aug 2021
- Abandoned
- 11 Nov 2024
- Attorney of record
- Anna Kurian Shaw
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treatment of diabetes complications; Pharmaceutical preparations for treatment of heart diseases or disorders, eye diseases or disorders, nervous system diseases or disorders, kidney diseases or disorders, cardiomyopathy, neuropathy, retinopathy, and nephropathy; Pharmaceutical preparations for inhibiting aldose reductase
Owner
- Applied Therapeutics, Inc., New York, NY, US
- Applied Therapeutics, Inc., New York, NY, US
Prosecution history
- 11 Nov 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Nov 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 23 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Mar 2024 — SOU EXTENSION 5 GRANTED
- 22 Mar 2024 — SOU EXTENSION 5 FILED
- 22 Mar 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Sept 2023 — SOU EXTENSION 4 GRANTED
- 19 Sept 2023 — SOU EXTENSION 4 FILED
- 19 Sept 2023 — SOU TEAS EXTENSION RECEIVED
- 14 Mar 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Mar 2023 — SOU EXTENSION 3 GRANTED
- 10 Mar 2023 — SOU EXTENSION 3 FILED
- 10 Mar 2023 — SOU TEAS EXTENSION RECEIVED
- 12 Sept 2022 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED